Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

1,345

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

September 30, 2007

Conditions
MeningitisMeningococcemiaPertussisTetanusDiphtheria
Interventions
BIOLOGICAL

T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.

Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular

BIOLOGICAL

Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.

Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap

Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular

Trial Locations (20)

13210

Syracuse

15241

Pittsburgh

18960

Sellersville

21201

Baltimore

27609

Raleigh

28779

Sylva

30062

Marietta

30189

Woodstock

37660

Kingsport

40004

Bardstown

43205

Columbus

44118

Cleveland

44308

Akron

45404

Dayton

72205

Little Rock

72401

Jonesboro

80303

Boulder

87108

Albuquerque

99202

Spokane

01801

Woburn

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00777257 - Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine | Biotech Hunter | Biotech Hunter